Anthos Therapeutics, Inc.

This phase 3 trial tested a new drug, abelacimab, against a standard blood thinner (dalteparin) to prevent dangerous blood clots from returning in people with gastrointestinal or genitourinary cancers. The study enrolled 417 adults with advanced cancer and a recent clot. It was t…

This study tested a new blood thinner, abelacimab, against the standard drug apixaban in about 1,150 people with cancer who had a blood clot. The goal was to see which drug better prevented new clots and caused less bleeding. The study was stopped early, but the results may still…